Chloroquine
- Generic Name
- Chloroquine
- Drug Type
- Small Molecule
- Chemical Formula
- C18H26ClN3
- CAS Number
- 54-05-7
- Unique Ingredient Identifier
- 886U3H6UFF
- Background
Chloroquine is an aminoquinolone derivative first developed in the 1940s for the treatment of malaria. It was the drug of choice to treat malaria until the development of newer antimalarials such as pyrimethamine, artemisinin, and mefloquine. Chloroquine and its derivative hydroxychloroquine have since been repurposed for the treatment of a number of other conditions including HIV, systemic lupus erythematosus, and rheumatoid arthritis.
The FDA emergency use authorization for hydroxychloroquine and chloroquine in the treatment of COVID-19 was revoked on 15 June 2020.
Chloroquine was granted FDA Approval on 31 October 1949.
- Indication
Chloroquine is indicated to treat infections of P. vivax, P. malariae, P. ovale, and susceptible strains of P. falciparum. It is also used to treat extraintestinal amebiasis.
Chloroquine is also used off label for the treatment of rheumatic diseases, as well as treatment and prophylaxis of Zika virus. Chloroquine is currently undergoing clinical trials for the treatment of COVID-19.
- Associated Conditions
- Discoid Lupus Erythematosus (DLE), Extraintestinal Amebiasis, Malaria, Polymorphic Light Eruption (PLE), Porphyria Cutanea Tarda, Rheumatoid Arthritis, Sarcoidosis, Acute, uncomplicated Malaria
An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older
- Conditions
- Malaria, Vivax
- Interventions
- First Posted Date
- 2024-10-30
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 300
- Registration Number
- NCT06666491
- Locations
- 🇮🇳
GSK Investigational Site, Surat, India
Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi
- Conditions
- Malaria,FalciparumAnemia in Children
- Interventions
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Liverpool School of Tropical Medicine
- Target Recruit Count
- 1000
- Registration Number
- NCT06083688
- Locations
- 🇲🇼
Malaria Alert Centre, Blantyre, Malawi
The Seven Trial: Exploiting the Unfolded Protein Response
- Conditions
- Pancreatic Cancer MetastaticPancreatic Adenocarcinoma Metastatic
- Interventions
- First Posted Date
- 2023-10-11
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- HonorHealth Research Institute
- Target Recruit Count
- 18
- Registration Number
- NCT06076837
- Locations
- 🇺🇸
Clinical Trials Nurse Navigator, Scottsdale, Arizona, United States
Therapeutic Efficacy of Chloroquine Plus Primaquine in the Treatment of Uncomplicated Plasmodium Vivax
- Conditions
- MalariaVivax MalariaChloroquineEfficacy
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Dinka Dugassa
- Target Recruit Count
- 100
- Registration Number
- NCT06044805
- Locations
- 🇪🇹
Shecha Health Center, Arba Minch, South Ethiopia, Ethiopia
Comparing Chemoprevention Drugs for School-based Malaria Control
- Conditions
- Anemia in ChildrenMalaria,Falciparum
- Interventions
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2023-08-07
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 646
- Registration Number
- NCT05980156
- Locations
- 🇲🇼
Kamuzu University of Health Sciences, Blantyre, Malawi
TES of Chloroquine for Pv in the Philippines in 2016
- First Posted Date
- 2023-07-25
- Last Posted Date
- 2023-07-25
- Lead Sponsor
- Research Institute for Tropical Medicine, Philippines
- Target Recruit Count
- 74
- Registration Number
- NCT05958797
ACT vs CQ With Tafenoquine for P. Vivax Mono-infection
- Conditions
- Malaria, VivaxMalariaPlasmodium Vivax Malaria
- Interventions
- Drug: Artemether-Lumefantrine plus Tafenoquine (450 mg adult dose)Drug: Dihydroartemisinin-piperaquine plus tafenoquine (450 mg adult dose)
- First Posted Date
- 2023-03-28
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Shoklo Malaria Research Unit
- Target Recruit Count
- 606
- Registration Number
- NCT05788094
- Locations
- 🇹🇭
Shoklo Malaria Research Unit (SMRU), Mae Sot, Tak, Thailand
Comparing Chemoprevention Approaches for School-based Malaria Control
- Conditions
- Malaria,FalciparumAnemia in Children
- Interventions
- First Posted Date
- 2022-02-17
- Last Posted Date
- 2022-11-15
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 746
- Registration Number
- NCT05244954
- Locations
- 🇲🇼
Kamuzu University of Health Sciences, Blantyre, Malawi
Southeast Asia Dose Optimization of Tafenoquine
- Conditions
- Plasmodium Vivax Malaria
- Interventions
- First Posted Date
- 2021-01-12
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 700
- Registration Number
- NCT04704999
- Locations
- 🇱🇦
Lao Oxford Mahosot Hospital Wellcome Trust Research Unit (LOMWRU), Vientiane, Lao People's Democratic Republic
🇻🇳Oxford University Clinical Research Unit (OUCRU), Binh Phuoc, Vietnam
🇰🇭Mahidol Oxford Tropical Medicine Research Unit (MORU), Cambodia, Siem Reap, Cambodia
Prevention With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19) (TS-COVID)
- First Posted Date
- 2020-11-13
- Last Posted Date
- 2021-10-07
- Lead Sponsor
- Fundacion Clinica Valle del Lili
- Target Recruit Count
- 3217
- Registration Number
- NCT04627467
- Locations
- 🇨🇴
Fundacion Valle del Lili, Cali, Valle Del Cauca, Colombia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.